Clinical Trial Update: Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD) [Phase 2]

View source ↗

Summary

Phase 2 open-label pharmacokinetics study of Centanafadine extended-release capsules in pediatric ADHD participants completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Centanafadine extended-release capsules (centanafadine)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Attention Deficit Hyperactivity Disorder | Phase 2 | Status: COMPLETED | Results posted: 2023-01-13